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Glomerular-derived proteins may activate tubular cells to
express the macrophage-directed chemokine monocyte
chemoattractant protein-1 (MCP-1/CCL2). Macrophages at
interstitial sites have a central role in directing renal scarring.
We have prospectively assessed the relationship between
albuminuria, urinary MCP-1/CCL2, interstitial macrophage
infiltration, in situ damage, and clinical outcomes in a large
group of patients with chronic kidney disease. We studied
215 patients and quantified albumin–creatinine ratio (ACR),
urinary MCP-1/CCL2, interstitial macrophage numbers, and
in situ damage. ACR correlated with urinary MCP-1/CCL2
(correlation 0.499; Po0.001), interstitial macrophage
numbers (correlation 0.481; Po0.001), and index of chronic
damage (correlation 0.363; Po0.001). Macrophage numbers
closely correlated with in situ damage (correlation 0.755;
Po0.001). By multivariate analysis ACR, urinary MCP-1/CCL2,
and interstitial macrophage numbers were interdependent.
By Kaplan–Meier survival analysis albuminuria, urinary MCP-1/
CCL2, interstitial macrophages, and chronic damage predict
the outcome. ACR, macrophage numbers, chronic damage,
and creatinine independently predicted renal survival. The
association of ACR with other variables was strongest in
patients with less advanced disease states. There is a close
association between albuminuria, urinary MCP-1/CCL2, and
interstitial macrophage infiltration with in situ damage and
clinical outcomes. These findings support the hypothesis that
albuminuria triggers tubular MCP-1/CCL2 expression with
subsequent macrophage infiltration. These processes may
represent the dominant pathway for the progression of renal
injury before the establishment of advanced renal scarring
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In chronic kidney disease, a progressive decline in renal func-
tion is associated with worsening tubulointerstitial disease
that is characterized by tubular atrophy and interstitial scar
formation.1,2 There is also an interstitial inflammatory
infiltrate in which the macrophage is prominent.3 Animal
models indicate that this cell type has a central role in the
initiation and progression of renal injury.4
The chemokine monocyte chemoattractant protein-1
(MCP-1/CCL2) is expressed at sites of injury and inflamma-
tion to direct macrophage recruitment; it ligates CC chemo-
kine receptor 2 (CCR2) to promote macrophage adhesion
and chemotaxis to disease sites. Increased tubular expression
of MCP-1/CCL2 is present in human progressive renal
disease,5,6 and interstitial inflammatory infiltrates express
CCR2.7,8 In animal models, blocking MCP-1/CCL2 or CCR2
is associated with reduced interstitial macrophage infiltration
and tubulointerstitial damage.9–12
In acute proliferative diseases such as lupus nephritis,
mesangiocapillary and crescentic glomerulonephritis, increa-
sed urinary MCP-1/CCL2 represents increased glomerular
expression of the chemokine.5 In chronic non-proliferative
disease, however, increased urinary levels probably reflect
tubular MCP-1/CCL2 expression,5,13 which itself correlates
with urinary albumin levels14 and interstitial macrophage
infiltration.6,13,15 Recent in vitro evidence has demonstrated
that tubular epithelial cells express MCP-1/CCL2 in response
to proteins including albumin.16,17 These data support the
hypothesis that albuminuria may accelerate disease progres-
sion through induction of tubular chemokine expression.
However, a direct link between these factors, macrophage
infiltration, and in situ damage in human disease has not
been demonstrated to date.
To address this, we have performed a large prospective
study of patients undergoing renal biopsy for investigation
of chronic kidney disease. We have used established and
validated methodologies to assess the association between
albuminuria, MCP-1/CCL2 expression, macrophage infiltra-
tion, and renal scarring. These data provide evidence in a
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heterogeneous group of diseases of an association between
albuminuria and progressive renal scarring secondary to
induction of MCP-1/CCL2 and subsequent macrophage
recruitment.
RESULTS
Patients
Two hundred and fifteen patients (130 males and 85 females)
with chronic renal disease were studied. Two hundred and
four patients had urine taken for albumin–creatinine ratio
(ACR) measurement prior to their biopsy. Table 1 shows the
histological diagnoses of the patients included in this study
and the results of the parameters analysed.
Albuminuria correlates with urinary MCP-1/CCL2
and interstitial macrophage numbers
By univariate analysis ACR correlates with urinary MCP-1/
CCL2 (correlation 0.499; Po0.001), interstitial macrophage
numbers (correlation 0.481; Po0.001), index of chronic
damage (correlation 0.363; Po0.001), and serum creatinine
(correlation 0.211; Po0.01) (Table 2; Figure 1). Categoriz-
ing urinary ACR into ranges of albuminuria recognized
to characterize very low (ACRo3 mg/mmol), low (ACR
3–99 mg/mmol), intermediate (ACR 100–299 mg/mmol),
and high (ACR4300 mg/mmol) risk of disease progression
showed a direct relationship between an incremental increase
in ACR, urinary MCP-1/CCL2 levels, and macrophage num-
bers, with the highest levels of chemokine and infiltrating
cells seen in patients with nephrotic range albuminuria
(ACR4300 mg/mmol) (Figure 2).
Interstitial macrophage numbers correlate with urinary
MCP-1/CCL2
Interstitial macrophage numbers were successfully quan-
tified in 174 (81%) patients. Extensive background staining
prevented analysis of tissue from 31 patients and tissue from
10 patients did not contain cortex. There was no significant
bias in macrophage quantification by the same observer
(mean 0.99; 95% confidence interval (CI) 0.98–1.07) or bet-
ween two observers (mean 0.95; 95% CI 0.96–1.11). The
limits of agreement of measurements by the same observer
were 0.81 (95% CI 0.75–0.88) and 1.21 (95% CI 1.11–1.31),
and between two observers were 0.70 (95% CI 0.62–0.79) and
1.29 (95% CI 1.14–1.46).
Macrophage numbers assessed by image analysis (mean
% area, 1.7671.14) correlated with urinary MCP-1/CCL2
levels (correlation 0.451; Po0.001) (Table 2; Figure 3).
Interstitial macrophage numbers correlate with chronic
damage and creatinine
Interstitial macrophage numbers correlated with the stage
of the disease process as assessed by index of chronic damage
Table 1 | Study population: clinical, pathological, and experimental characteristics
Histological diagnosis
(n) Age (years)
Creatinine
(lmol/l)
Index of chronic
damage (%) ACR (mg/mmol)
Urinary MCP-1/
CCL2 (pg/mg)
Interstitial
macrophages (%)
Thin GBM disease (n=44) 42714 (n=44) 86712 (44) 374 (44) 3877 (38) 114786 (38) 0.947 0.11 (38)
IgA nephropathy (43) 44715 (n=43) 1507147 (43) 23726 (43) 977183 (42) 2047212 (40) 1.4470.83 (33)
Ischaemic/hypertensive
nephropathy (42)
58713 (n=42) 2367114 (42) 42748 (42) 54795 (41) 2197185 (38) 2.2271.06 (35)
Focal segmental
glomerulosclerosis (30)
50715 (n=30) 140794 (30) 20716 (30) 3527395 (29) 3907327 (24) 1.8170.83 (22)
Membranous
nephropathy (20)
47716 (n=20) 112754 (20) 19724 (20) 3737380 (19) 2647212 (18) 2.3271.5 (14)
Diabetic nephropathy
(18)
57716 (n=18) 153781 (18) 30724 (18) 2747323 (17) 3547357 (17) 1.8670.96 (17)
Minimal change
nephropathy (5)
51723 (n=5) 108754 (5) 10712 (5) 8897441 (5) 169710 (2) 1.4270.25 (4)
Primary amyloidosis (4) 7977 (n=4) 3047301 (4) 43737 (4) 3887408 (4) 720724 (2) 5.1572.03 (3)
Light-chain nephropathy
(4)
68714 (n=4) 132741 (4) 30712 (4) 1567136 (4) 4477228 (4) 2.2070.55 (3)
Other (5) 56721 (n=5) 2037122 (5) 27727 (5) 1107156 (5) 2987208 (4) 2.5972.03 (5)
All (215) 50717 (n=215) 1537116 (215) 22725 (215) 1757300 (204) 2457243 (187) 1.7671.14 (174)
ACR=albumin–creatinine ratio; MCP-1/CCL2=chemokine monocyte chemoattractant protein-1; GBM=glomerular basement membrane; IgA=immunoglobulin A.
Table 2 | Univariate analysis of correlations between ACR, urinary MCP-1/CCL2, interstitial macrophage numbers, index of
chronic damage, and serum creatinine
Urinary ACR
Correlation; P-value (n)
Urinary MCP-1/CCL2
Correlation; P-value (n)
Interstitial macrophages
Correlation; P-value (n)
Index of chronic damage
Correlation; P-value (n)
Serum
creatinine (n)
Urinary ACR 1.000 (204)
Urinary MCP-1/CCL2 0.499; o0.001 (183) 1.000 (187)
Interstitial macrophages 0.481; o0.001 (165) 0.451; o0.001 (154) 1.000 (174)
Index of chronic damage 0.363; o0.001 (204) 0.333; o0.001 (187) 0.755; o0.001 (174) 1.000 (215)
Serum creatinine 0.211; o0.01 (204) 0.257; o0.001 (187) 0.698; o0.001 (174) 0.690; o0.001 (215) 1.000 (215)
ACR=albumin–creatinine ratio; MCP-1/CCL2=chemokine monocyte chemoattractant protein-1.
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(correlation 0.755; Po0.001) and serum creatinine (corre-
lation 0.690; Po0.001) (Table 2; Figure 4).
Multivariate analyses of correlation
Multivariate linear regression analysis of correlations between
the variables found that urinary ACR, urinary MCP-1/CCL2,
and interstitial macrophage numbers were interdependent.
Serum creatinine and index of chronic renal damage
were independent predictors of each other and of interstitial
macrophage numbers, but not of the other variables analysed
(Table 3).
Renal outcome
Data on renal outcome were available on 165 (77%) of the
215 patients at a mean of 832 days (7431) following their
renal biopsy. Twenty-seven patients reached the renal end
point (nine patients doubled their serum creatinine; 18
patients reached end-stage renal failure) after a mean period
of 439 days (range 1–1283 days; one patient with end-stage
focal segmental sclerosing glomerular disease commenced
dialysis at 1 day). Those who progressed were significantly
older (60716 years) than those who did not (49716 years)
(P¼ 0.002). Kaplan–Meier survival analyses found that high
levels of albuminuria, particularly ACR4300 mg/mmol, were
predictive of a poorer renal outcome. Similarly, those with
high levels of urinary MCP-1/CCL2, interstitial macrophages,
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Figure 1 | Plots of correlations between ACR and urinary MCP-1/
CCL2, and between ACR and interstitial macrophage numbers
(correlation; P-value). (a) Urinary ACR and urinary MCP-1/CCL2
(0.499; Po0.001). (b) Urinary ACR and interstitial macrophage
numbers (0.481; Po0.001).
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Figure 2 | Albuminuria range and associated urinary MCP-1/CCL2
and interstitial macrophage numbers. (a) Urinary ACR and urinary
MCP-1/CCL2 (ANOVA, Po0.001). (b) Urinary ACR and interstitial
macrophage numbers (ANOVA, Po0.001) (** and *, Bonferroni post-
hoc test significance Po0.001 and 0.01, respectively).
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Figure 3 | Plot of correlation between urinary MCP-1/CCL2 and
interstitial macrophage numbers (0.451; Po0.001).
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Figure 4 | Plots of correlation between interstitial macrophage
numbers and chronic damage and between interstitial macro-
phage numbers and serum creatinine. (a) Interstitial macrophage
numbers and index of chronic damage (0.755; Po0.001). (b)
Interstitial macrophage numbers and serum creatinine (0.698;
Po0.001).
Table 3 | Multivariate linear regression analysis of correlations between ACR, urinary MCP-1/CCL2, interstitial macrophage
numbers, index of chronic damage, and serum creatinine
Dependent variable
Urinary ACR
Correlation; P-value
Urinary MCP-1/CCL2
Correlation; P-value
Interstitial macrophages
Correlation; P-value
Index of chronic damage
Correlation; P-value
Serum creatinine
Correlation; P-value
Urinary ACR NA 0.343; o0.001 0.162; o0.01 NS NS
Urinary MCP-1/CCL2 0.336; o0.001 NA 0.175; o0.01 NS NS
Interstitial macrophages 0.352; o0.001 0.329; o0.001 NA 0.520; o0.001 0.339; o0.001
Index of chronic damage NS NS 0.263; o0.001 NA 0.457; o0.001
Serum creatinine NS NS 0.445; o0.001 0.359; o0.001 NA
ACR=albumin–creatinine ratio; MCP-1/CCL2=chemokine monocyte chemoattractant protein-1; NA=not applicable; NS=not statistically significant.
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and chronic damage had the poorest renal outcome
(Figure 5). Univariate Cox regression analysis found that
ACR, urinary MCP-1/CCL2, interstitial macrophage num-
bers, index of chronic damage, serum creatinine, and patient
age had a significant impact on renal outcome (Table 4).
Multivariate analysis found urinary ACR, interstitial macro-
phage numbers, index of chronic damage, and serum
creatinine to be independent variables that significantly
predicted renal survival (Table 4). Urinary MCP-1/CCL2 and
patients’ age and sex were not found to be significant.
Subset analyses
Histological diagnosis. To test further the unifying role of
albuminuria and MCP-1/CCL2 in interstitial inflammation
and damage, we analysed data from patients with immuno-
globulin A (IgA) nephropathy, focal segmental glomerulo-
sclerosis (FSGS), and ischaemic/hypertensive nephropathy
independently (Table 5). In each group, univariate analysis
demonstrated the correlation between urinary albumin and
MCP-1/CCL2 levels and urinary MCP-1/CCL2 and inter-
stitial macrophage numbers. In IgA nephropathy and focal
segmental glomerulosclerosis urinary ACR correlated with
interstitial macrophage numbers, but this association was not
present in ischaemic/hypertensive nephropathy. Multivariate
analyses of correlation and renal outcome analyses were not
performed as the patient numbers in individual disease
groups were relatively small.
Chronic damage. To assess whether the stage of disease
progression affected the relationships between ACR, urinary
MCP-1/CCL2, and interstitial macrophage numbers, we
analysed patients with an index of chronic damage of less
than 20% and compared them with those with an index
of 20% or greater. Univariate analysis showed that ACR,
urinary MCP-1/CCL2, and interstitial macrophage numbers
were highly significantly correlated in those patients (128
patients) with an index of chronic damage ofo20% (all with
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Figure 5 | Kaplan–Meier analysis of variables on renal outcome. (a) Urinary ACR (log rank statistic 14.01; Po0.005). (b) Urinary MCP-1/CCL2
(log rank statistic 7.26; Po0.026). (c) Interstitial macrophage numbers (log rank statistic 14.93; Po0.001). (d) Index of chronic damage (log rank
statistic 37.16; Po0.001).
Table 4 | Univariate and multivariate analysis of the impact of studied variables on renal survival
Interstitial
macrophages
Correlation;
P-value
Urinary MCP-
1/CCL2
Correlation;
P-value
Urinary ACR
Correlation;
P-value
Serum
creatinine
Correlation;
P-value
Index of chronic
damage
Correlation; P-value
Age
Correlation;
P-value Sex
Univariate Exp(B); P-value 107.2; o0.001 4.247; 0.012 2.149; o0.001 0.0002; o0.001 26.8; o0.001 1.039; 0.003 NS
Multivariate 6.02; 0.02 NS 9.154; 0.002 0.0001; 0.002 477; 0.003 NS NS
MCP-1/CCL2=chemokine monocyte chemoattractant protein-1; NS=not statistically significant.
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Po0.001). In patients with more chronic damage (n¼ 87),
there was close correlation between albuminuria and urinary
MCP-1/CCL2 (b¼ 0.463, Po0.001). Interstitial macrophage
numbers correlated with urinary MCP-1/CCL2 (b¼ 0.238,
P¼ 0.05), but not with the ACR (b¼ 0.011, P¼NS).
DISCUSSION
In these studies, we demonstrate an association between
albuminuria and a pathway for the development of renal
injury that progresses from the generation of MCP-1/CCL2
to macrophage recruitment and in situ damage in a
heterogeneous group of renal diseases. The strength of this
association is directly related to the amount of urinary
albumin leak; the strongest correlations exist in nephrotic
range albuminuria. Subset analyses of different types of renal
disease also show that the association between interstitial
macrophage infiltration and damage is strong in all disease
states and at different levels of renal scarring. However, the
relationship between ACR, urinary MCP-1/CCL2, and inter-
stitial macrophage numbers is strongest in those patients
with lower levels of scarring and affected by disorders
associated with distinct patterns of glomerular injury, such as
IgA nephropathy and focal segmental glomerulosclerosis. In
more advanced renal disease, including ischaemic/hyper-
tensive nephropathy, these associations are less strong,
indicating that other mechanisms may have an increasingly
important role on the recruitment of these cells in this
setting.
The role of macrophages in the progression of chronic
renal injury is well established; their presence is a consistent
feature of the tubulointerstitial changes that occur irrespec-
tive of the original disease.1,2 Experimental models indicate
that macrophages mediate damage at this site through a
number of mechanisms, which include the generation of
radical oxygen species, nitric oxide, complement factors, and
proinflammatory cytokines.4 Macrophages also affect sup-
porting matrix and vasculature through the expression of
metalloproteinases and vasoactive peptides and promote the
transdifferentiation of tubular epithelial cells into interstitial
fibroblasts, which themselves contribute to renal scarring.18
The chemokine MCP-1/CCL2 acting through its receptor
CCR2 is a potent chemoattractant for macrophages and has
been demonstrated to direct macrophage infiltration and
injury in a number of renal and non-renal diseases.9–12,19,20
Recent experiments using novel gene therapy techniques10,11
in progressive kidney disease have specifically blocked tubular
MCP-1/CCL2 expression with a subsequent reduction in
interstitial macrophage infiltration and in situ injury. In
human chronic non-proliferative kidney diseases, MCP-1/
CCL2 expression has been demonstrated by immuno-
histochemistry5,6 and in situ hybridization5,21 to be primarily
restricted to tubular epithelial cells. These cells are local to
peritubular capillaries and can therefore direct the infiltration
of macrophages from the intravascular compartment.
Relatively small studies of human chronic disease have
(i) demonstrated associations between semiquantitative
assessment of MCP-1/CCL2 expression in situ and macro-
phage infiltration5,6 and damage,5 and (ii) correlated urinary
MCP-1/CCL2 with ACR13 and macrophage infiltration.14 In a
retrospective study of 25 patients, there was more tubular
MCP-1/CCL2 expression and macrophage infiltration in
patients with progressive disease.15 The study reported here
Table 5 | Univariate analysis of correlation between ACR, urinary MCP-1/CCL2, interstitial macrophage numbers, index of
chronic damage, and serum creatinine by histological diagnosis: (a) IgA nephropathy; (b) focal segmental glomerulosclerosis
and (c) ischaemic/hypertensive nephropathy
Urinary ACR
Correlation;
P-value (n)
Urinary MCP-1/CCL2
Correlation;
P-value (n)
Interstitial macrophages
Correlation;
P-value (n)
Index of chronic damage
Correlation;
P-value (n)
Serum creatinine
Correlation;
P-value (n)
(a) IgA nephropathy
Urinary ACR 1.000 (42)
Urinary MCP-1/CCL2 0.633; o0.001 (40) 1.000 (40)
Interstitial macrophages 0.604; o0.001 (33) 0.521; o0.001 (32) 1.000 (33)
Index of chronic damage 0.53; o0.001 (42) 0.514; 0.001 (40) 0.825; o0.001 (33) 1.000 (43)
Serum creatinine 0.398; o0.01 (42) 0.438 o0.01 (40) 0.817; o0.001 (33) 0.713; o0.001 (43) 1.000 (43)
(b) Focal segmental glomerulosclerosis
Urinary ACR 1.000 (29)
Urinary MCP-1/CCL2 0.792; o0.001 (24) 1.000 (24)
Interstitial macrophages 0.529; o0.05 (21) 0.586; o0.05 (18) 1.000 (22)
Index of chronic damage 0.347; NS (29) 0.033; NS (24) 0.534; o0.05 (22) 1.000 (30)
Serum creatinine 0.202; NS (29) 0.093; NS (24) 0.421; 0.05 (22) 0.375; o0.05 (30) 1.000 (30)
(c) Ischaemic/hypertensive nephropathy
Urinary MCP-1/CCL2 0.318; 0.05 (37) 1.000 (38)
Urinary ACR 1.000 (40)
Interstitial macrophages 0.129; NS (33) 0.427; o0.05 (31) 1.000 (35)
Index of chronic damage 0.190; NS (40) 0.287; NS (38) 0.789; o0.001 (35) 1.000 (42)
Serum creatinine 0.186; NS (40) 0.268; NS (38) 0.606; o0.001 (35) 0.606; o0.001 (42) 1.000 (42)
ACR=albumin–creatinine ratio; IgA=immunoglobulin A; MCP-1/CCL2=chemokine monocyte chemoattractant protein-1; NS, not statistically significant.
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is much larger than previous analyses, is prospective, quanti-
tative, and powered for subset analyses, and to explore asso-
ciations that demonstrate a pathogenic role with an impact
on clinical end points.
Several theories have been proposed to explain the
link between the initial renal insult and progressive tubulo-
interstitial inflammatory injury. In acute proliferative renal
diseases, glomerular-derived cytokines may have effects on
cells downstream in the nephron by, for example, activating
tubular epithelial cells to express leukocyte adhesion
molecules and proinflammatory cytokines, including MCP-
1/CCL2.22 This theory is most relevant to crescentic mem-
branoproliferative glomerulonephritides, where marked
increases in glomerular expression of proinflammatory
cytokines have been demonstrated.5,6,23
We analysed a group of patients with chronic kidney
diseases where previous studies have shown that proteinuria
is a rigorous predictor of tubulointerstitial disease progres-
sion.24 As glomerular injury evolves, tubular epithelial cells
are exposed to higher concentrations of glomerular filtrated
proteins, including albumin; these may promote phenotypic
changes necessary for the recruitment of macrophages to
interstitial sites.24 In vitro proximal tubular epithelial cells
express MCP-1/CCL2 in a dose–response manner to pro-
tein.16,17 In animal models, strategies that decrease albumi-
nuria are also associated with a reduction in tubular MCP-1/
CCL2 expression and interstitial inflammation.25–27 The
results of this study indicate that albuminuria-induced
tubular MCP-1/CCL2 expression is important in interstitial
macrophage recruitment and disease progression in human
chronic kidney disease. As well as demonstrating strong
correlations between ACR, urinary MCP-1/CCL2, interstitial
macrophage numbers and scarring, we found that these factors
predict renal outcome. The association between urinary MCP-
1/CCL2 levels, macrophage infiltration, and clinical outcomes
had not previously been prospectively studied.
Consistent with other studies, nephrotic range albumi-
nuria was associated with the highest risk of disease
progression, and these patients had the highest levels of
urinary MCP-1/CCL2 and interstitial macrophage numbers.
To demonstrate causality however requires the means of
reducing albuminuria or blocking its effect on tubular cells,
in the absence of other factors that may trigger this pathway.
The protein overload proteinuria model is the best animal
model currently available to study the effects of proteinuria
on the development of tubulointerstitial disease. In this
setting, where no glomerular abnormalities are induced, the
importance of tubular derived MCP-1/CCL2 in disease
progression has been demonstrated.10
Albumin is clearly not the only serum protein that
is leaked into the urinary space in disease. Experiments
with human proximal tubular epithelial cells (PTEC) have
demonstrated that serum proteins of molecular weight
40–100 kDa increase proximal tubular epithelial cell MCP-1/
CCL2 expression.16 Albumin has a molecular weight within
this range (60 kDa), as does transferrin, which has also
has biological effects on proximal tubular epithelial cells,
including increasing chemokine expression.28 Larger-mole-
cular-weight proteins also enter the urinary space in disease
states. These include immunoglobulins, which also increase
tubular MCP-1/CCL2 expression.29 The biological effects
of these larger-molecular-weight proteins are particularly
important in renal prognosis, as their detection in urine is
more predictive of disease progression than albumin.24
Indeed, in minimal change disease there is selective protein-
uria, where large-molecular-weight proteins are not leaked.
This disease is not associated with the development of
tubulointerstitial disease and renal failure. There is evidence
that the fatty acids bound to albumin are an important
determinant of biological effect, and the relative lack of fatty
acid content of albumin in minimal change disease may also
be associated with a benign prognosis.30 In vitro however, the
use of lipated albumin resulted in MCP-1/CCL2 expression
by proximal tubular epithelial cells at levels similar to
de-lipidated albumin.17
The results from our subset analyses suggest that
proteinuria-induced tubular MCP-1/CCL2 expression is
particularly important in the recruitment of macrophages
early in disease. Correlations between interstitial macrophage
numbers, urinary MCP-1/CCL2, and albumnuria were parti-
cularly significant in those patients with an index of chronic
damage o20%. However, in those at a more advanced stage
the ACR did not significantly correlate with interstitial
macrophage numbers, although both factors were indepen-
dently correlated with urinary MCP-1/CCL2 and macrophage
numbers. Thus, other factors may become increasingly
important in promoting MCP-1/CCL2-dependent interstitial
macrophage infiltration with disease progression. These
may include tissue hypoxia, which can generate tubular
MCP-1/CCL2 through activation of the renin–angiotensin
system.31,32 Hypoxia also increases adhesion molecule expres-
sion by endothelial cells and tubular epithelial cells. Recruited
macrophages may themselves promote a hypoxic microenvir-
onment. Macrophages colocalize with tubular cells at sites
of vascular endothelial growth factor downregulation, and
in vitro macrophage-derived cytokines downregulate tubular
vascular endothelial growth factor expression.33 Vascular
endothelial growth factor is an important proangiogenic
cytokine. In patients with hypertensive/ischaemic nephro-
pathy where tissue hypoxia is likely, we found that interstitial
macrophage numbers did not directly correlate with albumi-
nuria, although albuminuria and macrophage numbers
remained significantly correlated with urinary MCP-1/CCL2.
A reduction in proteinuria to o1 g per day in response to
blood pressure reduction and renin–angiotensin system
blockade is associated with a better renal prognosis.24
Patients who do not achieve this response have a significantly
poorer prognosis. We did not collect data on renin–angio-
tensin system blockade therapy at the time of their biopsy,
nor prospectively studied the effect of renin–angiotensin
system blockade introduction on those patients who subse-
quently commenced this treatment. We would hypothesize,
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however, that renin–angiotensin system blockade would
reduce urinary MCP-1/CCL2 expression. In proteinuric renal
disease, baseline and urinary MCP-1/CCL2 levels are unlikely
to be a more specific indicator of prognosis than measuring
proteinuria in those with proteinuric renal disease. However,
in non-proteinuric diseases such as ischaemic nephropathy,
measuring MCP-1/CCL2 may be valuable. This requires
further study.
This study highlights the central role of the interstitial
macrophage in chronic kidney disease progression in respect
of tubular-derived MCP-1/CCL2. Therefore, this chemokine,
the receptor CCR2, or the factors that increase expression of
either molecule may represent attractive therapeutic targets.
The use of gene therapy and chemokine receptor antagonists
that target MCP-1/CCL2-dependent interstitial macrophage
recruitment in animal models has yielded encouraging
results.9–12 Animal models studying chemokine receptors in
glomerulonephritides highlight a further layer of complexity.
Models of anti-glomerular basement membrane disease in
mice deficient of the chemokine receptor CCR2 developed
more severe disease.34 These findings may indicate that MCP-
1/CCL2 and/or CCR2 may have important homeostatic roles
in some settings.
In summary, we show a close association between
albuminuria, urinary MCP-1/CCL2, and interstitial macro-
phage numbers with in situ damage and clinical outcomes in
human chronic kidney disease. This relationship is strongest
in early disease and less pronounced in ischaemic/hyper-
tensive nephropathy. These findings support the theory that
increased albuminuria triggers tubular MCP-1/CCL2 expres-
sion with subsequent macrophage infiltration. These pro-
cesses may represent the dominant pathway for the progres-
sion of renal injury with limited renal scarring.
MATERIALS AND METHODS
Patients
Following local ethical committee permission and informed
consent, we recruited patients who underwent percutaneous renal
biopsy in our department for investigation of renal disease between
June 1999 and June 2002. Renal biopsy specimens were obtained
prospectively from 215 patients with chronic kidney disease under
real-time ultrasound guidance using a 16-G semi-automatic biopsy
needle. The specimens were immediately fixed in formal saline and
glutaraldehyde. Urine for quantification of MCP-1/CCL2 and ACR
was collected immediately before the biopsy. A normal ACR is
o2.5 mg/mmol for men, and o3.5 mg/mmol for women. An ACR
of 100 mg/mmol approximates to a 24-h urinary albumin excretion
of 1 g, whereas an ACR of 300 mg/mmol or more approximates to
nephrotic range albuminuria. Multiplying by 8.8 converts the ACR
from mg/mmol creatinine to mg/mg creatinine.
Patients found to have mesangiocapillary glomerulonephritis,
crescentic glomerulonephritis, or lupus nephritis were excluded
from further study, as in these diseases the glomeruli is a significant
source of any MCP-1/CCL2 detected in the urine.5 Patients with
chronic nonproliferative diseases were included where urinary MCP-
1/CCL2 probably reflects tubular expression.
Follow-up data were available on 165 patients (77%) of the total
cohort and we analysed clinical outcomes for this group. We defined
a doubling in serum creatinine from the time of renal biopsy and/or
initiation of renal replacement therapy (calculated in days) as the
end point for renal outcome. Data were unavailable on 50 patients
who had been referred back to their primary care physician or
referring hospital. The majority (35 patients) had been diagnosed as
having either thin glomerular basement membrane disease or IgA
nephropathy as a cause of their isolated microscopic haematuria.
Renal diagnosis
Histological diagnoses were made on formal saline- and glutar-
aldehyde-fixed biopsy specimens. Light microscopic sections (2 mm)
were examined in orthodox ways and immunostaining carried out
with an immunoperoxidase method for IgG, IgA, IgM, and the
complement component C9. The glutaraldehyde-fixed specimen was
embedded in Araldite and sectioned for electron microscopy when
indicated.
Urinary MCP-1/CCL2 assay
Quantification of urinary MCP-1/CCL2 was performed using a
commercially available sandwich ELISA kit according to the manu-
facturers’ instructions (R&D Systems, Minneapolis, MN, USA).
These levels were corrected for urinary creatinine concentration.
Immunohistochemistry for macrophages
The immunohistochemical detection of tissue macrophages was
performed using established methods. Briefly, dewaxed and
rehydrated paraffin-embedded sections (2 mm) were processed for
antigen retrieval in 0.01 mol/l of sodium citrate buffer (pH 6.0) at
951C for 30 min. Slides were then incubated with 0.3% hydrogen
peroxide to block endogenous peroxidase activity, followed by
sequential treatment with 0.1% avidin and 0.01% biotin (Dako Ltd,
Ely, UK) to block endogenous biotin activity. Three-stage indirect
immunohistochemistry was performed by sequential incubation
with a primary mouse monoclonal antibody directed against the
pan-macrophage antigen CD68 (5 mcg/ml; clone PG-M1; Dako Ltd)
for 1 h, a biotinylated secondary rabbit anti-mouse antibody
(50 mcg/ml; Dako Ltd) for 1 h, and a horse radish peroxidase-
conjugated streptavidin–biotin complex (Dako Ltd) for 20 min.
Between two incubations, sections were washed in Tris-buffered
saline (pH 7.4). All incubations were performed at room
temperature. Binding was visualized by the addition of 30,3-
diaminobenzidine (Vector Laboratories Ltd, Peterborough, UK).
Sections were then counterstained with Mayer’s haematoxylin
(Sigma-Aldrich, Poole), except those used for quantitative analysis,
which were left unstained (see below). Mouse IgG1 (Dako Ltd) was
used as an isotype control antibody and substituted for the primary
antibody on serial sections.
Tissue sections were batched and stained in one sitting over a
course of 4 days to help maintain consistency in the technique used
between samples. The PG-M1 monoclonal antibody was used to
identify the macrophage-specific antigen CD68. The protein is
present in the cytosol of all macrophages and its expression does not
vary with the maturity and activation status of the cell. This is in
contrast with CD14, which has also been been used in immuno-
histochemical studies as a marker for macrophages.35
Interstitial macrophage quantification
An interactive image analysis system was used for blinded
assessment of interstitial macrophage numbers. This technique has
previously been reported as a reliable method for the analysis of
human and animal renal sections.36,37 Coded sections stained for
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CD68 were visualized at  200 magnification and the image
captured digitally by an Aequitas image database and image archive
management system (Dynamic Data Links, Cambridge). Each image
was then converted to a two-colour scale image by Aequitas image
analysis software (Dynamic Data Links). By altering the threshold,
the image was processed so that positive staining was represented by
black pixels and measured as a percentage of the area of the total
image analysed. For each patient, the mean measurement of five
randomly selected non-confluent microscopic fields of renal cortex
was determined. Glomerular staining was excluded from the analysis
by the computer software. Sections where background staining
made it impossible to digitally differentiate specific staining were
excluded from analysis.
Quantification of chronic damage
The extent of chronic damage within each biopsy specimen was
assessed by an established and validated method that is a rigorous
predictor of renal outcome.38 Briefly, one routinely prepared section
of each specimen was stained by periodic acid-methenamine silver
and examined under a microscope. Chronically scarred tissue was
identified as glomeruli showing global sclerosis but not segmental
sclerosis, areas of interstitial fibrosis, which appeared more solid and
deeply stained than normal or oedematous interstitial tissues, and
atrophic tubules, defined as tubules smaller than normal, with
thickened basement membranes, or tubules larger than normal, with
thin epithelium, including those large enough to be considered
cysts. Arteries and arterioles were not judged to have chronic
damage unless they were completely occluded. Images at a
magnification of  10 were captured digitally by the Aequitas
image database and image archive management system (Dynamic
Data Links). Using Aequitas image analysis software, the extent of
scarring observed within the cortex of the kidney biopsy section was
quantified and expressed as a percentage of total tissue analysed.
Statistics
To assess the validity of the methods used to quantify interstitial
macrophages, inter- and intra-observer variabilities were tested. For
inter-observer variation, two observers measured 20 randomly
selected specimens independently; one observer had helped to
develop the method (D Zehnder) and the other would measure the
entire series (KS Eardley). The 20 specimens were also measured
twice at intervals by Eardley to test for intra-observer variability.
Agreement was assessed by the method of Bland and Altman after
log transformation (necessary because the differences between
measurements were proportional to the mean).39 This method
gives the bias, or mean difference between measurements, and limits
of agreement, or 2 s.d.’s either side of the mean, with 95% CIs for
the bias and limits of agreement, all expressed as ratios when
back-transformed.
Linear regression analyses were performed to determine correla-
tions between normally distributed data variables. When required, as
determined by normality testing for skewness, data variables were
normalized by log transformation. In the case of serum creatinine
the reciprocal was used, and for index of chronic damage 1 was
added to the value prior to log transformation. Correlations are
presented by expressing the b correlation coefficient along with the
P-value. Linear regression stepwise multivariate analysis of these
correlations with a dependent variable was also performed.
Comparison of data means was performed using either a two-tailed
‘t’ test or analysis of variance (ANOVA) with Bonferroni post-hoc
tests when comparing multiple groups. Univariate and multivariate
analyses of the impact of variables on renal outcome were performed
using Cox regression analysis. Renal outcome was also assessed by
Kaplan–Meier survival analysis with log rank testing. Kaplan–Meier
analyses of urinary MCP-1/CCL2 and interstitial macrophage
numbers were performed after their categorization in tertiles. All
statistical tests were performed using SPSS for Windows, version
12.0, and the level of significance was set at Po0.05.
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